Polio vaccine attenuated vaccine strains. In 1958, the National Institutes of Health created a special committee on live polio vaccines. The various vaccines were carefully evaluated for their ability to induce immunity to polio, while retaining a low incidence of neuropathogenicity in monkeys. Large-scale clinical trials performed in the Soviet Union in late 1950s to early 1960s by Mikhail Chumakov and his colleagues demonstrated safety and high efficacy of the vaccine. Based on these results, the Sabin strains were chosen for worldwide distribution. Fifty-seven nucleotide substitutions distinguish the attenuated Sabin 1 strain from its virulent parent (the Mahoney serotype), two nucleotide substitutions
Sabin Vaccine Institute Development, the Global Network for Neglected Tropical Diseases, and Vaccine Advocacy and Education. Through its Product Development Partnership (PDP), Sabin has worked with organizations such as King Saud University, Texas Children's Hospital Center, International Vaccine Institute, and George Washington University School of Medicine & Health Sciences toward its goals, with funding and support from the Bill & Melinda Gates Foundation, the National Institute of Allergy and Infectious Diseases, the Dutch Ministry of Foreign Affairs, the Brazilian Ministry of Health and other benefactors. In 2012, Sabin partnered with International Vaccine Institute to combine their research, development, and promotion efforts in Asia,